NCT07246304 2025-11-24
TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC
TCRCure Biopharma Ltd.
Phase EARLY_PHASE1 Recruiting
Clinical Trials
8 trialsNCT06092047 2025-05-16
UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies.
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase EARLY_PHASE1 Recruiting
NCT06532643 2024-09-19
Safety and Efficacy of Anti-CD20/CD30 CAR-T Cells in Subjects with Relapsed/Refractory Lymphoma
Shanghai First Song Biotechnology Co., LTD
Phase EARLY_PHASE1 Recruiting
NCT03692663 2022-08-01
Study of Anti-PSMA CAR NK Cell (TABP EIC) in Metastatic Castration-Resistant Prostate Cancer
Allife Medical Science and Technology Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT03943472 2021-08-31
BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma
Hrain Biotechnology Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT04626726 2020-11-13
Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation
Hebei Senlang Biotechnology Inc., Ltd.
Phase EARLY_PHASE1 Unknown
NCT04626752 2020-11-13
CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma
Hebei Senlang Biotechnology Inc., Ltd.
Phase EARLY_PHASE1 Unknown
NCT04626765 2020-11-13
CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia
Hebei Senlang Biotechnology Inc., Ltd.
Phase EARLY_PHASE1 Unknown